DBV drops as accelerating spending raises funding concerns

** Shares in DBV Technologies DBV.PA drop 8% after the French biopharmaceutical company said its operational expenses rose 79% to €66.3 million in Q3

** "We are once again surprised by the high level of cash burn, especially as the company enters a regulatory phase," broker Portzamparc says

** Brokerage warns that accelerating cash burn, which has reduced the company's cash runway to less than one year, raises the prospect of additional funding and shareholder dilution

** It adds that the expense increase primarily comes from research and development costs alongside preparations for a US commercial launch

** Including today's fall, the stock has dropped by 49% YTD

($1 = 0.8971 euros)